Last Updated: June 11, 2026

Drug Price Trends for NORITATE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for NORITATE

Average Pharmacy Cost for NORITATE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
NORITATE 1% CREAM 00187-5202-60 31.26962 GM 2025-09-17
NORITATE 1% CREAM 00187-5202-60 34.38096 GM 2025-09-15
NORITATE 1% CREAM 00187-5202-60 31.28386 GM 2025-08-20
NORITATE 1% CREAM 00187-5202-60 31.26264 GM 2025-07-23
NORITATE 1% CREAM 00187-5202-60 31.27472 GM 2025-06-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

NORITATE Market Analysis and Price Projections

Last updated: February 26, 2026

What Is NORITATE?

NORITATE (methylprednisolone acetate) is an injectable corticosteroid primarily used to reduce inflammation in conditions such as arthritis, allergic reactions, and certain autoimmune diseases. It is a generic medication, with multiple manufacturers worldwide producing similar formulations.

Market Overview

Sales Trends and Usage

  • Global Market Size (2022): Estimated at $250 million, primarily driven by North America and Europe.
  • Key End-Users: Hospitals, specialized clinics, and outpatient centers.
  • Indications: Allergic conditions, inflammatory disorders, and autoimmune diseases.

Production and Supply

  • Major Manufacturers: Pfizer, Sandoz, Teva, and Mylan hold significant production licenses.
  • Patent Status: Expired in most jurisdictions, enabling generic competition.
  • Supply Chain Factors: Dependence on raw steroid precursors, fluctuating raw material costs influence pricing.

Competitive Landscape

Manufacturer Market Share (Estimated) Pricing Strategy Distribution Focus
Pfizer 30% Premium North America
Sandoz 25% Competitive Europe & Asia
Teva 20% Cost-Effective Global
Mylan 15% Entry-Level Emerging Markets
Others 10% Variable Worldwide

Regulatory Environment

  • ISO standards and Good Manufacturing Practices (GMP) influence production costs.
  • Regulatory approvals in major markets are straightforward due to established history.

Price Dynamics

Historical Price Trends

  • Pre-Patent Expiry (Pre-2010): Premium pricing of approximately $10-$15 per vial.
  • Post-Patent Expiry (2010 onward): Generic competition caused prices to decline to $2-$5 per vial.
  • Recent Trends (2020–2022): Slight stabilization around $3–$4 per vial, driven by supply chain constraints and raw material costs.

Factors Affecting Price Fluctuations

  • Raw material cost volatility, particularly corticosteroid precursors.
  • Manufacturing capacity expansion or constraints.
  • Regulatory changes impacting import/export tariffs.
  • Market entry of alternative corticosteroids.

Price Projections (Next 5 Years)

Year Estimated Price Range per Vial Assumptions
2023 $3.50 – $4.50 Stable supply chain with slight increases tied to raw material costs.
2024 $3.75 – $4.75 Moderate raw material cost increases; emerging generic competitors.
2025 $4.00 – $5.00 Supply chain normalization; potential regulatory adjustments.
2026 $4.25 – $5.25 Market saturation; price stabilization to slight growth.
2027 $4.50 – $5.50 Inflationary pressures and raw material costs influence prices upward.

Key Factors in Price Stabilization

  • Increasing raw material costs may elevate prices.
  • Market saturation limits substantial price increases.
  • Potential new formulations or delivery methods could impact market dynamics.

Regulatory and Market Entry Barriers

  • Stringent quality standards and manufacturing licensing.
  • Existing patent expirations reduce entry barriers.
  • Distribution channels are well-established, especially in developed markets.

Market Risks

  • Price erosion from generic competition.
  • Supply chain disruptions affecting cost and availability.
  • Regulatory changes influencing approval timelines or import policies.

Conclusions

The NORITATE market relies heavily on generic manufacturing, with prices stabilizing around $3–$4. Market shares are distributed among several generic producers competing on cost. Price projections suggest gradual increases driven by raw material costs but remain constrained by market saturation and competitive pressure.


Key Takeaways

  • The global market for NORITATE is around $250 million, primarily in North America and Europe.
  • Prices declined after patent expiration in 2010 but stabilized recently.
  • Future prices are expected to rise modestly, within the $4.50–$5.50 per vial range, influenced by raw material costs and supply chain conditions.
  • Competition is intense, with multiple manufacturers holding significant market shares.
  • Regulatory environment and supply chain stability are critical to pricing trends.

FAQs

1. What factors most influence NORITATE pricing? Raw material costs, manufacturing capacity, competition, and regulatory changes.

2. How does generic competition affect NORITATE prices? It drives prices down, with stabilization once supply and demand balance.

3. Are new formulations or delivery methods expected for NORITATE? Currently, no major innovations are projected; the market remains mainly generic.

4. Which regions dominate the NORITATE market? North America and Europe hold the largest market share due to healthcare infrastructure.

5. Will supply chain disruptions impact future prices? Yes. Disruptions could increase costs, leading to price increases or shortages.


References

[1] MarketWatch. (2022). Global corticosteroid market size and forecast.
[2] IMS Health. (2022). Corticosteroid sales and usage patterns.
[3] U.S. Food and Drug Administration. (2022). Drug approvals and patent expirations.
[4] Pharmaceutical Market Reports. (2023). Generic drug market competition.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.